- Home
- AIRE vs IMMX Comparison
AIRE vs IMMX Comparison
Compare AIRE & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRE
- IMMX
- Stock Information
- Founded
- AIRE 2021
- IMMX 2014
- Country
- AIRE United States
- IMMX United States
- Employees
- AIRE N/A
- IMMX N/A
- Industry
- AIRE
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- AIRE
- IMMX Health Care
- Exchange
- AIRE Nasdaq
- IMMX Nasdaq
- Market Cap
- AIRE 53.2M
- IMMX 61.1M
- IPO Year
- AIRE N/A
- IMMX 2021
- Fundamental
- Price
- AIRE $1.22
- IMMX $2.17
- Analyst Decision
- AIRE Strong Buy
- IMMX Strong Buy
- Analyst Count
- AIRE 1
- IMMX 1
- Target Price
- AIRE $3.00
- IMMX $7.00
- AVG Volume (30 Days)
- AIRE 148.4K
- IMMX 268.7K
- Earning Date
- AIRE 12-31-2024
- IMMX 11-12-2024
- Dividend Yield
- AIRE N/A
- IMMX N/A
- EPS Growth
- AIRE N/A
- IMMX N/A
- EPS
- AIRE N/A
- IMMX N/A
- Revenue
- AIRE $379,241.00
- IMMX N/A
- Revenue This Year
- AIRE $571.65
- IMMX N/A
- Revenue Next Year
- AIRE $168.35
- IMMX $200.00
- P/E Ratio
- AIRE N/A
- IMMX N/A
- Revenue Growth
- AIRE 18.11
- IMMX N/A
- 52 Week Low
- AIRE $0.53
- IMMX $1.26
- 52 Week High
- AIRE $2.50
- IMMX $7.50
- Technical
- Relative Strength Index (RSI)
- AIRE 53.68
- IMMX 53.37
- Support Level
- AIRE $1.12
- IMMX $1.88
- Resistance Level
- AIRE $1.50
- IMMX $2.44
- Average True Range (ATR)
- AIRE 0.11
- IMMX 0.32
- MACD
- AIRE 0.01
- IMMX -0.02
- Stochastic Oscillator
- AIRE 28.21
- IMMX 34.94
About AIRE reAlpha Tech Corp.
ReAlpha Tech Corp is a real estate technology company that develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability; and has an app for investment into the properties that it purchased aimed at retail investors. The company's reportable segments are; Platform Services, which derives key revenue, and the Rental business segment.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.